Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Tvardi Therapeutics, Inc. clinical trials
The registry lists 28 studies whose lead sponsor is Tvardi Therapeutics, Inc. or one of 1 company grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the Tvardi Therapeutics, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Tvardi Therapeutics, Inc..
- Cara Therapeutics, Inc.24 studies →Acquired — became part of Tvardi Therapeutics, Inc., Apr 15, 2025 · source ↗
Something wrong?
- Tvardi Therapeutics, Incorporated4 studiesSame company
Something wrong?
Focus areas
Conditions Tvardi Therapeutics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 28 of 28.
- A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaRecruitingNCT05440708Phase 1/2
Sponsor listed in the registry: Tvardi Therapeutics, Incorporated
- Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerTerminatedNCT05384119Phase 1
Sponsor listed in the registry: Tvardi Therapeutics, Incorporated
- Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisCompletedNCT05671835Phase 2
Sponsor listed in the registry: Tvardi Therapeutics, Incorporated
- Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced CancersCompletedNCT03195699Phase 1
Sponsor listed in the registry: Tvardi Therapeutics, Incorporated
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia ParestheticaTerminatedNCT05978063Phase 2/3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusTerminatedNCT05356403Phase 3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusTerminatedNCT05342623Phase 3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic DermatitisTerminatedNCT05387707Phase 3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe PruritusCompletedNCT03617536Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe PruritusTerminatedNCT03995212Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)CompletedNCT04706975Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis PatientsCompletedNCT05533008Phase 1
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Intermediate-Size Patient Population Expanded Access Program for Intravenous DifelikefalinApproved for marketingNCT05031546
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT03636269Phase 3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)CompletedNCT03422653Phase 3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic DermatitisCompletedNCT04018027Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT03998163Phase 3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT03281538Phase 3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or KneeCompletedNCT02944448Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT02858726Phase 2/3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy SubjectsCompletedNCT04019574Phase 1
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy SubjectsCompletedNCT03947970Phase 1
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal SurgeryCompletedNCT02542384Phase 2/3
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or KneeCompletedNCT02524197Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic PruritusCompletedNCT02229929Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy SurgeryCompletedNCT00877799Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy SurgeryCompletedNCT01789476Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.
- Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy SurgeryCompletedNCT01361568Phase 2
Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.